Biomimetic mesoporous vectors enabling the efficient inhibition of wild-type isocitrate dehydrogenase in multiple myeloma cells
Sign Up to like & getrecommendations! Published in 2021 at "Microporous and Mesoporous Materials"
DOI: 10.1016/j.micromeso.2021.111320
Abstract: Abstract The discovery of isocitrate dehydrogenases (IDHs) mutations in several malignancies has brought to the approval of drugs targeting IDH1/2 mutants in cancers. More recently it has been suggested that the enzymatic inhibition of IDHs… read more here.
Keywords: drug; multiple myeloma; agi 6780; myeloma cells ... See more keywords
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2018-05-850826
Abstract: Proteasome inhibitors (PI) are extensively used for the therapy of multiple myeloma (MM) and mantle cell lymphoma. However, patients continuously relapse or are intrinsically resistant to this class of drugs. Here, to identify targets that… read more here.
Keywords: inhibitor; agi 6780; inhibition; inhibition enhances ... See more keywords